Pyoderma gangrenosum
Pyoderma gangrenosum هڪ نادر، سوزش واري چمڙي جي بيماري آهي جنهن ۾ دردناڪ پسٽول يا نوڊولس السر بڻجي ويندا آهن جيڪي اڳتي وڌندا آهن. Pyoderma gangrenosum وبائي مرض نه آهي. علاج ۾ شامل ٿي سگھي ٿو corticosteroids، ciclosporin، يا مختلف monoclonal antibodies. جيتوڻيڪ اهو ڪنهن به عمر جي ماڻهن کي متاثر ڪري سگهي ٿو، اهو اڪثر ڪري ماڻهن کي متاثر ڪري ٿو انهن جي 40s ۽ 50s ۾.
☆ 2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
ulcerative colitis سان هڪ شخص جي ٽنگ تي.
References
Pyoderma gangrenosum چمڙي جي هڪ نادر حالت آهي جيڪا ڳاڙهي يا واڱڻائي وارين ڪنارن سان دردناڪ السر پيدا ڪري ٿي. اها هڪ سوزش واري بيماري جي طور تي درجه بندي ڪئي وئي آهي ۽ هڪ گروپ جو حصو آهي جنهن کي نيوٽروفيلڪ ڊرماتوز سڏيو ويندو آهي. Pyoderma gangrenosum جو سبب پيچيده آهي، جنهن ۾ جننياتي طور تي متاثر ٿيندڙ ماڻهن ۾ پيدائشي ۽ موافقت واري قوت مدافعت جا مسئلا شامل آهن. تازي طور تي، محققن تي ڌيان ڏنو آهي بال جي ڦڦڙن تي بيماري جي شروعاتي نقطي جي طور تي.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum هڪ نادر چمڙي جي حالت آهي جيڪا انتهائي دردناڪ السر پيدا ڪري ٿي. جڏهن ته اسان ان جي سبب کي مڪمل طور تي نه سمجهي سگهون ٿا، اسان ڄاڻون ٿا ته ان ۾ ڪجهه مدافعتي سيلن جي وڌندڙ سرگرمي شامل آهي. بيماري جو علاج اڃا تائين آسان ناهي. اسان وٽ مختلف دوائون آهن جيڪي مدافعتي نظام کي دٻائن ٿيون يا ان جي سرگرمي کي تبديل ڪن ٿيون. ان سان گڏ، اسان زخم جي علاج ۽ درد جي انتظام تي پڻ ڌيان ڏيون ٿا. Corticosteroids ۽ cyclosporine اڪثر علاج لاء پهريون انتخاب آهن، پر تازو، اتي وڌيڪ تحقيق ڪئي وئي آهي بايولوجيڪ علاج جهڙوڪ TNF-α inhibitors استعمال ڪرڻ. اهي حياتيات کي ترجيح ڏني وئي آهي، خاص طور تي مريضن ۾ ٻين سوزش واري حالتن سان، ۽ اهي بيماري جي عمل ۾ اڳ ۾ استعمال ڪيا ويندا آهن.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
